FDA Expands Oversight of Cell and Gene Therapies

被引：0
|
作者：
Wechsler, Jill
机构：
来源：
BIOPHARM INTERNATIONAL | 2022年 / 35卷 / 11期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [21] FDA pharmaceutical quality oversight
    Yu, Lawrence X.
    Woodcock, Janet
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 491 (1-2) : 2 - 7
  • [22] FDA tightens human oversight
    Dove, A
    NATURE MEDICINE, 2001, 7 (06) : 646 - 646
  • [23] FDA tightens human oversight
    Alan Dove
    Nature Medicine, 2001, 7 : 646 - 646
  • [24] FDA approval of Casgevy and Lyfgenia: a dual breakthrough in gene therapies for sickle cell disease
    Rahmat, Zainab Syyeda
    Ali, Mohammad Haris
    Talha, Muhammad
    Al Hasibuzzaman, Md
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (09): : 4966 - 4968
  • [25] A Review of the Cost-Effectiveness Evidence for FDA-Approved Cell and Gene Therapies
    Abuloha, Sumaya
    Niu, Shu
    Adirika, Darlene
    Harvey, Benjamin P.
    Svensson, Mikael
    HUMAN GENE THERAPY, 2024, 35 (11-12) : 365 - 373
  • [26] NIH, FDA pledge more oversight after death in gene therapy experiment
    不详
    ISSUES IN SCIENCE AND TECHNOLOGY, 2000, 16 (03) : 25 - 26
  • [27] FDA scrutinizes human stem cell therapies
    Jeffrey L Fox
    Nature Biotechnology, 2008, 26 : 598 - 599
  • [28] FDA scrutinizes human stem cell therapies
    Fox, Jeffrey L.
    NATURE BIOTECHNOLOGY, 2008, 26 (06) : 598 - 599
  • [29] FDA expands Eqvalan label
    不详
    JOURNAL OF EQUINE VETERINARY SCIENCE, 2003, 23 (06) : 242 - 242
  • [30] FDA expands Adequan indications
    不详
    LARGE ANIMAL PRACTICE, 1997, 18 (01): : 7 - 7
12345